[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100470233":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":23,"responsibleParty":75,"collaborators":77,"id":97,"slug":98,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":9,"eligibilityCriteria":102,"healthyVolunteers":99,"sex":103,"minAge":104,"maxAge":10,"enrollmentInfo":105,"targetDuration":10,"studyType":108,"phases":10,"briefSummary":109,"conditions":110,"keywords":10,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"University Health Network, Toronto","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"MOHCCN-O",null,"Tumor tissue and blood samples will be collected from patients who are enrolled in this study but do not yet have the molecular profiling data that are required to meet the gold standard criteria. Data will include: pathology, clinical biomarkers, imaging diagnostic information, whole genome and epi-genome sequencing of tumor and normal tissues, immunoprofiling of tumor tissues and\u002For peripheral blood, bioinformatic annotation of molecular information, and longitudinal clinical and outcome data.",[13],{"name":14,"affiliation":5,"role":15},"Lillian Siu, MD","PRINCIPAL_INVESTIGATOR",[17],{"name":18,"role":19,"phone":20,"phoneExt":21,"email":22},"PM2C Central Office","CONTACT","416-946-4501","3486","MOHCCN@uhn.ca",[24,45,63],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Kingston Health Sciences Centre","RECRUITING","Kingston","Ontario","K7L 2V7","Canada","CA",{"type":33,"coordinates":34},"Point",[35,36],-76.48098,44.22976,{"lat":36,"lon":35},[39,43],{"name":40,"role":19,"phone":41,"phoneExt":10,"email":42},"Heather Grant","613-548-2517","granth@queensu.ca",{"name":44,"role":15,"phone":10,"phoneExt":10,"email":10},"Amber Simpson, PhD",{"facility":46,"status":47,"city":48,"state":28,"zip":49,"country":30,"countryCode":31,"cosmosGeoPoint":50,"geoPoint":54,"contacts":55},"Ottawa Health Research Institute","NOT_YET_RECRUITING","Ottawa","K1Y 4E9",{"type":33,"coordinates":51},[52,53],-75.69812,45.41117,{"lat":53,"lon":52},[56,61],{"name":57,"role":19,"phone":58,"phoneExt":59,"email":60},"Leonard Angka, PhD","613-737-8899","71111","langka@ohri.ca",{"name":62,"role":15,"phone":10,"phoneExt":10,"email":10},"Rebecca Auer, MD",{"facility":64,"status":26,"city":65,"state":28,"zip":66,"country":30,"countryCode":31,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Princess Margaret Cancer Centre","Toronto","M5G2M9",{"type":33,"coordinates":68},[69,70],-79.39864,43.70643,{"lat":70,"lon":69},[73,74],{"name":18,"role":19,"phone":20,"phoneExt":21,"email":22},{"name":14,"role":15,"phone":10,"phoneExt":10,"email":10},{"type":76,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[78,80,82,84,86,88,89,91,93,95],{"name":79,"class":6},"Princess Margaret Hospital, Canada",{"name":81,"class":6},"Ontario Institute for Cancer Research",{"name":83,"class":6},"Terry Fox Research Institute",{"name":85,"class":6},"Queen's University, Kingston, Ontario",{"name":87,"class":6},"Ottawa Hospital Research Institute",{"name":25,"class":6},{"name":90,"class":6},"Windsor Regional Hospital",{"name":92,"class":6},"University of Windsor",{"name":94,"class":6},"London Health Sciences Centre",{"name":96,"class":6},"London Health Sciences Centre Research Institute","100470233","marathon-of-hope-cancer-centres-network-study-for-ontario-mohccn-o-100470233",false,"NCT05403177","Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)","Inclusion Criteria:\n\n1. Patients with histological and\u002For cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy\n2. All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through:\n\n   1. Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1)\n   2. Have sufficient biospecimens (tumor and\u002For blood samples) available for more comprehensive molecular and immunophenotypic characterization\n3. Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling.\n4. Participating patients must agree to share their anonymized clinical and genomic data\n\nExclusion Criteria:\n\nNone.","ALL","18 Years",{"count":106,"type":107},500,"ESTIMATED","OBSERVATIONAL","The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients",[111,112,113,114,115,116,117,118,119,120,121,122],"Breast Cancer","Colorectal Cancer","Pancreas Cancer","Kidney Cancer","Prostate Cancer","Ovary Cancer","Head and Neck Cancer","Leukemia","Lymphoma","Lung Cancer","Melanoma","Solid Tumor","2026-06-09",{"date":125,"type":126},"2026-06-10","ACTUAL",{"date":128,"type":126},"2022-06-23",{"date":130,"type":107},"2030-10",{"name":5,"class":6},3]